- VIVOLTA has signed a long-term agreement for a new production facility at High Tech Campus Eindhoven to expand its electrospun medical implant manufacturing.
- The expansion adds 400 square metres of ISO Class 7 cleanrooms and new MediSpin™ production lines to meet growing demand for regenerative implant manufacturing.
VIVOLTA, a specialist in electrospun medical implant manufacturing, has announced a long-term agreement for a dedicated production facility at High Tech Campus Eindhoven. The move represents a key milestone in the company’s expansion, driven by increasing customer demand for industrial-scale manufacturing of regenerative medical implants.
The new facility will include 400 square metres (4,300 square feet) of ISO Class 7-qualified cleanrooms and MediSpin™ production lines — VIVOLTA’s proprietary platform for high-throughput, medical-grade electrospinning. This expansion complements the company’s existing ISO 13485-certified site and further establishes VIVOLTA as a fully integrated CDMO partner in the field of regenerative medicine and implantable devices.
“This expansion reflects the next phase of our journey. We’re scaling our capabilities in step with our customers’ demands, ensuring they can rely on VIVOLTA for full development and large-scale manufacturing under one roof.”
Denis Leissing, CEO of VIVOLTA
Located within one of Europe’s foremost innovation hubs, the High Tech Campus Eindhoven facility will enable VIVOLTA to enhance collaboration, attract specialised talent, and strengthen its operational capacity across key therapeutic areas including cardiovascular, wound care, orthopaedics, and soft tissue repair.
